Featured Research

from universities, journals, and other organizations

New anti-inflammatory substance: Biochemists ID important messenger in immune system

Date:
November 10, 2010
Source:
Kiel University
Summary:
The messenger interleukin-27 plays an important role when the human body blocks inflammations, according to new research by an international team of scientists.

The messenger interleukin-27 plays an important role when the human body blocks inflammations, according to new research.

The discovery was made by an international research team, of which the Kiel Professors Joachim Grötzinger and Stefan Rose-John, as well as the doctoral candidate, Björn Spudy, are a part of. The research findings of the scientists from Kiel, the US and Great Britain were published Nov. 7 in the online advance edition of Nature Immunology.

The human immune system reacts to bodily injuries and infections with inflammation. This is important for the healing process, but can result in harmful effects if it becomes chronic. Inflammation is triggered by messengers such as the cytokine interleukin-6 (IL-6). This peptide hormone latches on to special receptor molecules on cells and compels inflammation. "We observed that another cytokine, interleukin-27, can counteract this effect," explained Professor Joachim Grötzinger, from the Institute of Biochemistry at Kiel University. "IL-27 latches on to the same receptors as IL-6 and thus inhibits the inflammatory reaction." The Kiel biochemists were able to support the international research team with their knowledge of IL-6 in particular. According to Grötzinger, "We have dedicated ourselves to this topic for over 20 years." Professor Stefan Rose-John added: "We hope that these fundamental findings will one day be able to aid the healing of chronic inflammatory diseases."

The Christian-Albrechts-Universität zu Kiel (CAU) has proven international expertise as a North German research university in the field of Life Sciences. This fact is emphasised by the cluster of excellence Inflammation at Interfaces, with which the CAU was successful in the first round of the national Excellence Initiative, together with the University of Lübeck and the Research Center Borstel. The Collaborative Research Centre (CRC) 877, "Proteolysis as a Regulatory Event in Pathophysiology," whose spokesperson is Rose-John and in which Grötzinger is also involved, substantiates the competence of Kiel in the field of Life Sciences as well. CRC 877 deals with signalling pathways within and between cells, which are triggered by the fission of proteins.


Story Source:

The above story is based on materials provided by Kiel University. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jason S Stumhofer, Elia D Tait, William J Quinn III, Nancy Hosken, Björn Spudy, Radhika Goenka, Ceri A Fielding, Aisling C O'Hara, Yi Chen, Michael L Jones, Christiaan J M Saris, Stefan Rose-John, Daniel J Cua, Simon A Jones, Merle M Elloso, Joachim Grötzinger, Michael P Cancro, Steven D Levin, Christopher A Hunter. A role for IL-27p28 as an antagonist of gp130-mediated signaling. Nature Immunology, 2010; DOI: 10.1038/ni.1957

Cite This Page:

Kiel University. "New anti-inflammatory substance: Biochemists ID important messenger in immune system." ScienceDaily. ScienceDaily, 10 November 2010. <www.sciencedaily.com/releases/2010/11/101108185916.htm>.
Kiel University. (2010, November 10). New anti-inflammatory substance: Biochemists ID important messenger in immune system. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/11/101108185916.htm
Kiel University. "New anti-inflammatory substance: Biochemists ID important messenger in immune system." ScienceDaily. www.sciencedaily.com/releases/2010/11/101108185916.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins